Comparative Pharmacology
Head-to-head clinical analysis: DYNACIRC CR versus LEXXEL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DYNACIRC CR versus LEXXEL.
DYNACIRC CR vs LEXXEL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dihydropyridine calcium channel blocker that selectively inhibits calcium ion influx across cardiac and vascular smooth muscle cell membranes, leading to vasodilation and reduced peripheral vascular resistance.
LEXXEL is a combination of felodipine, a dihydropyridine calcium channel blocker that inhibits calcium influx into vascular smooth muscle and cardiac muscle, causing vasodilation and reduced myocardial contractility, and enalapril, an angiotensin-converting enzyme (ACE) inhibitor that prevents conversion of angiotensin I to angiotensin II, reducing vasoconstriction, aldosterone secretion, and sodium reabsorption.
Isradipine extended-release (DynaCirc CR) is indicated for hypertension. Initial dose: 5 mg orally once daily. Titrate based on blood pressure response; maximum dose 10 mg once daily.
1 tablet (felodipine 5 mg / enalapril 5 mg) orally once daily, may increase to 2 tablets once daily after 2-4 weeks if needed.
None Documented
None Documented
Terminal half-life approximately 7-8 hours; sustained due to controlled-release formulation.
Enalapril: ~1.3 hours; Enalaprilat: terminal half-life ~35-38 hours, with multiple-dose accumulation half-life ~11 hours; effective half-life for ACE inhibition ~24 hours.
Primarily hepatic metabolism with biliary excretion; 20% renal, 80% fecal.
Renal: ~35-50% as unchanged drug (enalaprilat), biliary/fecal: ~15-30% as metabolites and unchanged drug; total renal elimination of enalaprilat accounts for ~60-80% of dose.
Category C
Category C
Calcium Channel Blocker
ACE Inhibitor + Calcium Channel Blocker